Produced in collaboration with the American Macular Degeneration Foundation (AMDF).
This patient education activity is sponsored by Gyroscope.
If you are at risk for or diagnosed with age-related macular degeneration (AMD) or geographic atrophy (GA), you may be considering participating in a clinical trial, but also have questions such as: How will a clinical trial benefit me? Am I eligible to participate? What is gene therapy for AMD? And how are my health and safety protected?
For answers to questions like these and more, watch an expert panel of clinicians, patient representatives, and fellow patients discuss the clinical-trial process and how it relates to AMD. Watch on-demand today.
By watching this program, you’ll learn about:
- The role of genes in the development and progression of dry AMD and GA
- How participation in a clinical trial of gene therapy for dry AMD or GA can enhance the quality of one’s vision and that of others
- What to expect if you participate in a gene-therapy trial for dry AMD or GA
- The patient’s role in the research process, including commonly used words and the role of different stakeholders (e.g., regular eye doctor, research doctor, institutional review boards)
- Strategies to locate a clinical trial and determine how one can be a good candidate for participation
Rishi Singh, MD
Professor of Ophthalmology, Lerner College of Medicine Case Western Reserve University Staff Physician, Cole Eye Institute, Cleveland Clinic Foundation
Rishi P. Singh, MD, is a staff surgeon at the Cole Eye Institute, Cleveland Clinic and Professor of Ophthalmology at the Lerner College of Medicine in Cleveland Ohio. He also currently serves as the medical director of informatics at the Cleveland Clinic.
He specializes in the treatment of medical and surgical retinal disease such as diabetic retinopathy, retinal detachment, and age-related macular degeneration. Dr. Singh has authored more than 170 peer reviewed publications, books, and book chapters and serves as the principal investigator of numerous national clinical trials advancing the treatment of retinal disease. Dr. Singh is the former president on the Retina World Congress and is on the board of the American Society of Retina Specialists.
Grants, Advocacy and Partnerships Director, American Macular Degeneration Foundation
Matthew Levine is the grants, advocacy, and partnerships director of the American Macular Degeneration Foundation (AMDF) in Northampton, Massachusetts. For the past 18 years, his professional career has been in the nonprofit, vision research grantmaking community, working with thought leaders and researchers to advance solutions for those affected by vision loss and blindness. Previously, at Research to Prevent Blindness, Inc., Matthew directed marketing and communications activities accompanying the distribution of more than $120 million to vision researchers. He has worked with chairs of departments of ophthalmology, research directors, scientists, and colleagues at other foundations to develop programs that empower those affected by loss-of-sight to lead fulfilling lives.
Duncan Creed, EM
Patient with AMD
Duncan Creed, EM, was a sales engineer, selling engineered industrial machinery in Colorado, Arizona, the Netherlands, Virginia, Ohio, Louisiana and various other locations. At 20 years of age, Duncan learned that he had a severe color blindness condition. At 45, Duncan had 3 cataract surgeries on each eye with implants and 20/20 vision finally. In his early 70s, he was diagnosed with muscular dystrophy (MD), and he joined a clinical study on the effects of Parkinson’s medication on MD for about 5 years. During those years, Duncan learned that his MD was described as Geographic Atrophy. In addition, his age-related macular degeneration (AMD) has stabilized with some loss of closeup depth perception and color vision. Currently, Duncan is enjoying life with his wife Connie and their cat.